Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
Accelerating pharmaceutical patent expiries and pipeline failures are driving historic acquisition demand, anchoring biotechnology fundamentals even as benchmark Treasury yields surpass five percent.
Full Quick Take
Accelerating pharmaceutical patent expiries and pipeline failures are driving historic acquisition demand, anchoring biotechnology fundamentals even as benchmark Treasury yields surpass five percent.
Capitalizing on improved biotech sentiment driven by FDA leadership changes, strong M&A including AbbVie's $10.9 billion acquisition of portfolio company Apogee, and positive late-stage oncology data at ASCO.
Full Quick Take
Capitalizing on improved biotech sentiment driven by FDA leadership changes, strong M&A including AbbVie's $10.9 billion acquisition of portfolio company Apogee, and positive late-stage oncology data at ASCO.
Driven by AI semiconductor infrastructure (SK hynix, Samsung) and healthcare innovation (Lantheus M&A, CVS GLP-1). The manager rotated from richly valued names into Adobe, Fujifilm, UniCredit, and Booking Holdings, viewing market concentration as creating value dislocations.
Full Quick Take
Driven by AI semiconductor infrastructure (SK hynix, Samsung) and healthcare innovation (Lantheus M&A, CVS GLP-1). The manager rotated from richly valued names into Adobe, Fujifilm, UniCredit, and Booking Holdings, viewing market concentration as creating value dislocations.
Utilities Plus outperformed in Q2 2026 despite rate headwinds, benefiting from small/mid-cap regulated utility strength and data center power demand. The portfolio added to Xcel Energy on valuation.
Full Quick Take
Utilities Plus outperformed in Q2 2026 despite rate headwinds, benefiting from small/mid-cap regulated utility strength and data center power demand. The portfolio added to Xcel Energy on valuation.
Capitalizing on deeply discounted small-cap healthcare opportunities. The concentrated portfolio benefited from M&A activity, strong product launches at Liquidia and Electromed, and a 106% gain on Avanos acquisition.
Full Quick Take
Capitalizing on deeply discounted small-cap healthcare opportunities. The concentrated portfolio benefited from M&A activity, strong product launches at Liquidia and Electromed, and a 106% gain on Avanos acquisition.
The concentrated portfolio now holds significant cash following exits, with new position AnaptysBio offering 50-80% upside as GSK litigation approaches trial in July.
Full Quick Take
The concentrated portfolio now holds significant cash following exits, with new position AnaptysBio offering 50-80% upside as GSK litigation approaches trial in July.
Westfield trimmed AI exposure after semiconductors hit technical extremes, rotating into Healthcare, Industrials, and Financials. Healthcare offers compelling value with earnings inflection and $1.4 trillion pharma M&A firepower.
Full Quick Take
Westfield trimmed AI exposure after semiconductors hit technical extremes, rotating into Healthcare, Industrials, and Financials. Healthcare offers compelling value with earnings inflection and $1.4 trillion pharma M&A firepower.
Concentrated small-cap healthcare value fund delivered strong long-term returns despite Q1 underperformance. Avanos Medical takeout at 72% premium exemplifies M&A-driven value realization strategy.
Full Quick Take
Concentrated small-cap healthcare value fund delivered strong long-term returns despite Q1 underperformance. Avanos Medical takeout at 72% premium exemplifies M&A-driven value realization strategy.
Capital markets are reopening with follow-on activity tripling year-over-year. The concentrated biotech portfolio focuses on transformative life sciences assets with major oncology catalysts expected at upcoming medical conferences.
Full Quick Take
Capital markets are reopening with follow-on activity tripling year-over-year. The concentrated biotech portfolio focuses on transformative life sciences assets with major oncology catalysts expected at upcoming medical conferences.
Arbitrage strategy benefited from biotech acquisitions and energy sector strength during Iran conflict. Fund positioned in pending deals including AES Corp and Tri Pointe Homes with continued M&A momentum expected.
Full Quick Take
Arbitrage strategy benefited from biotech acquisitions and energy sector strength during Iran conflict. Fund positioned in pending deals including AES Corp and Tri Pointe Homes with continued M&A momentum expected.
RTW Bio outperformed biotech indices despite -6.4% Q1 return as sector valuations hit new lows. Portfolio concentrated in high unmet need rare diseases and oncology with strong FDA support.
Full Quick Take
RTW Bio outperformed biotech indices despite -6.4% Q1 return as sector valuations hit new lows. Portfolio concentrated in high unmet need rare diseases and oncology with strong FDA support.
Baron Health Care Fund matched benchmark returns in Q3 2025, driven by strong biotechnology stock selection including argenx and Insmed. AI-enabled healthcare solutions like RadNet and Heartflow also contributed.
Full Quick Take
Baron Health Care Fund matched benchmark returns in Q3 2025, driven by strong biotechnology stock selection including argenx and Insmed. AI-enabled healthcare solutions like RadNet and Heartflow also contributed.
Mid-cap growth fund weathered Q1 volatility through defensive positioning in healthcare distributors and waste management while technology holdings faced AI spending and tariff headwinds. Managers remain constructive on valuations, expecting policy clarity to drive recovery.
Full Quick Take
Mid-cap growth fund weathered Q1 volatility through defensive positioning in healthcare distributors and waste management while technology holdings faced AI spending and tariff headwinds. Managers remain constructive on valuations, expecting policy clarity to drive recovery.
The Gabelli ABC Fund employs arbitrage strategies focused on merger and acquisition opportunities. Q1 2025 saw $885 billion in global M&A activity despite regulatory headwinds under the new Trump administration.
Full Quick Take
The Gabelli ABC Fund employs arbitrage strategies focused on merger and acquisition opportunities. Q1 2025 saw $885 billion in global M&A activity despite regulatory headwinds under the new Trump administration.
Baird's small/mid cap growth strategy slightly outperformed in a challenging Q1.8% drop. AI spending concerns and tariff uncertainty drove market volatility.
Full Quick Take
Baird's small/mid cap growth strategy slightly outperformed in a challenging Q1.8% drop. AI spending concerns and tariff uncertainty drove market volatility.
With early 2025 success in M&A situations including three acquisition wins. Focus on special situations and valuation discipline drives uncorrelated alpha generation despite challenging market conditions.
Full Quick Take
With early 2025 success in M&A situations including three acquisition wins. Focus on special situations and valuation discipline drives uncorrelated alpha generation despite challenging market conditions.
The fund participated in 58 of 98 opportunities, with standout performances from contested takeovers like Namoi Cotton and special situations like Global Data Centre Group. Strong M&A pipeline and predicted 2025 rebound support continued opportunity flow.
Full Quick Take
The fund participated in 58 of 98 opportunities, with standout performances from contested takeovers like Namoi Cotton and special situations like Global Data Centre Group. Strong M&A pipeline and predicted 2025 rebound support continued opportunity flow.
Outperforming biotech indices. The fund focuses on transformative life sciences assets with 54 core positions spanning genetic medicines, obesity treatments, and rare diseases.
Full Quick Take
Outperforming biotech indices. The fund focuses on transformative life sciences assets with 54 core positions spanning genetic medicines, obesity treatments, and rare diseases.
Outperforming TSX Composite's -0.5%. Fund maintains high conviction in quality Canadian small caps with D2L education software addition at significant discount to private valuations.
Full Quick Take
Outperforming TSX Composite's -0.5%. Fund maintains high conviction in quality Canadian small caps with D2L education software addition at significant discount to private valuations.
Completing 44 deals since July inception. Fund focuses on high-probability M&A transactions with 3-5 month holding periods, emphasizing downside protection and diversification.
Full Quick Take
Completing 44 deals since July inception. Fund focuses on high-probability M&A transactions with 3-5 month holding periods, emphasizing downside protection and diversification.
Regional banks trading below book value, and commercial real estate opportunities. Portfolio benefits from ongoing biotech M&A activity and positioning for Fed rate cuts to benefit rate-sensitive holdings.
Full Quick Take
Regional banks trading below book value, and commercial real estate opportunities. Portfolio benefits from ongoing biotech M&A activity and positioning for Fed rate cuts to benefit rate-sensitive holdings.
Despite spread tightening since August as market confidence improved following regulatory wins, the strategy remains attractive with 11.1% average annualized yields versus 4% historically.
Full Quick Take
Despite spread tightening since August as market confidence improved following regulatory wins, the strategy remains attractive with 11.1% average annualized yields versus 4% historically.
Small-cap value manager substantially increased position in distressed CDMO Lifecore Biomedical after 66% decline from loan covenant default. Views this as balance sheet problem, not business problem, with secular biologics tailwinds intact.
Full Quick Take
Small-cap value manager substantially increased position in distressed CDMO Lifecore Biomedical after 66% decline from loan covenant default. Views this as balance sheet problem, not business problem, with secular biologics tailwinds intact.